Rate My Professor Victor Chuang

Dr. Victor Chuang is a Senior Lecturer in the Faculty of Health Sciences at Curtin University, Perth, Australia, where he has contributed for over 18 years as a dedicated pharmacy educator and researcher. He holds a BPharm (Hons) from the University of Science Malaysia (1989-1993), an MSc in Biopharmaceutics from Kumamoto University (1997-1999), and a PhD from the Graduate School of Pharmaceutical Sciences at Kumamoto University (1999-2002). His career trajectory includes serving as Associate Professor at the School of Pharmacy, Monash University Malaysia (December 2017-February 2019), Lecturer at the School of Pharmacy, University of Auckland (April 2016-June 2017), and earlier research positions such as at the School of Pharmacy, University of Otago (November 2011-February 2012). As a registered pharmacist and pharmaceutical scientist, Chuang articulates his mission as: "I am a pharmacist and pharmaceutical scientist trying to understand life from the perspective of pharmacy. I intend to solve clinical issues with scientific methods." He actively teaches pharmacy units at Curtin, including Foundations of Pharmaceutics (PHAR2000).

Chuang's research focuses on protein-drug interactions, particularly human serum albumin (HSA), encompassing ligand-binding properties, redox characteristics, oxidative stress markers, and pharmaceutical strategies for drug delivery and therapy. His prolific output includes 107 publications amassing over 4,700 citations. Standout works are "Practical aspects of the ligand-binding and enzymatic properties of human serum albumin" (Biological and Pharmaceutical Bulletin, 2002; 1,176 citations), "Albumin–drug interaction and its clinical implication" (Biochimica et Biophysica Acta-General Subjects, 2013; 587 citations), "Pharmaceutical strategies utilizing recombinant human serum albumin" (Pharmaceutical Research, 2002; 450 citations), "Redox properties of serum albumin" (Biochimica et Biophysica Acta-General Subjects, 2013; 290 citations), "Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases" (PLoS One, 2014; 216 citations), and "Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer" (Biomaterials, 2017; 158 citations). Research interests include proteins, protein purification, antioxidant activity, biomaterials, pharmaceutical development, antimicrobials, medicinal and pharmaceutical chemistry, high-performance liquid chromatography, genetic engineering, and method validation. His contributions advance understanding of HSA modifications for clinical applications in chronic diseases and drug formulation.